COPENHAGEN, Denmark, August 12, 2026
SNIPR announced new clinical evidence supporting the translational potential of SNIPR001, its engineered CRISPR-enhanced phage therapeutic designed to selectively target Escherichia coli (E. coli), following publication of a compassionate-use case report. The patient, who had a difficult-to-treat infection associated with multidrug-resistant (MDR) E. coli, received SNIPR001 through intravenous, topical and intralesional administration alongside standard-of-care treatment, including antibiotics and adjunctive therapies. According to the published report, treatment was associated with rapid healing of abdominal lesions and sustained regression of disease burden, with an intra-abdominal malakoplakia mass decreasing from 745 cm³ at baseline to 82 cm³ after one year, representing an 89% reduction. Follow-up urine and tissue cultures were negative following treatment, and no phage-related adverse events were reported during administration. The case supported an emergency investigational new drug (eIND) application and provides additional real-world clinical experience for SNIPR001.
SNIPR001 Demonstrates Potential in Difficult-to-Treat E. coli Infection
SNIPR001 is an engineered CRISPR-armed phage therapy designed to selectively target E. coli. In the reported compassionate-use case, the therapy was administered through multiple routes in combination with conventional treatment. The reported clinical response included substantial reduction of the intra-abdominal malakoplakia mass and negative follow-up cultures from urine and tissue. Investigators described the case as evidence of the potential for precision phage therapy in antibiotic-resistant and intracellular infections, particularly where conventional therapeutic options are limited. However, the evidence comes from an individual compassionate-use case and does not establish the safety or efficacy of SNIPR001 in a broader patient population.
Phase 1 and Phase 1b/2a Development Supports Further Evaluation
SNIPR is developing SNIPR001 primarily for the prevention of E. coli bloodstream infections in patients with hematological malignancies who are at risk of neutropenia, while also investigating its potential to directly treat active E. coli infections. The company previously completed a U.S. Phase 1a study, in which no safety signals were identified and target engagement with E. coli was observed in the gut of healthy participants without significant differences in overall gut microbiome composition compared with placebo. A randomized, double-blind, placebo-controlled Phase 1b/2a study has completed recruitment and is evaluating orally administered SNIPR001 in patients with hematological cancer. The study is assessing safety, tolerability, pharmacokinetics and pharmacodynamics in 24 patients. SNIPR001 has also received FDA Fast Track designation for prevention of bloodstream E. coli infections in patients with hematological malignancies at risk of neutropenia.
Advertisement
CRISPR-Enhanced Phage Platform Targets Drug-Resistant Bacteria
SNIPR001 combines bacteriophage targeting with CRISPR-Cas technology to selectively eliminate E. coli while aiming to minimize disruption of beneficial bacteria. Preclinical research published in Nature Biotechnology demonstrated activity against multidrug-resistant E. coli strains and specificity toward E. coli, with no off-target effects observed in the non-E. coli strains tested. The emerging clinical evidence, including the compassionate-use case, provides additional translational information as SNIPR advances its precision antimicrobial platform. SNIPR001 remains an investigational medicinal product and has not been approved by the FDA, EMA or any other regulatory authority, and its safety and efficacy have not been established. The latest case therefore represents an encouraging clinical signal rather than definitive evidence of therapeutic effectiveness.
Source:SNIPR press release
